Cytokeratin 7 by IHC-12376 - Technical only, 12379 - Technical & interpretation
Test info
Cytokeratin 7 by IHC
12376 - Technical only, 12379 - Technical & interpretation
LAB12376
LAB12379
LAB12379
CK7
All IHC stains will include a positive control tissue
- CK7 is found in a large number of cell types including many ductal and glandular epithelia (biliary and pancreatic ducts, lung alveoli, breast, ovary, endometrium, renal collecting ducts, urothelium, thyroid, placental trophoblasts, and mesothelium)
- CK7 and CK20 can be helpful in determining the site of origin of tumors, based on the staining profile
| Immunophenotype | Tumor |
|---|---|
| CK20+/CK7+ | Ovarian mucinous carcinoma Pancreatic carcinoma Transitional cell carcinoma |
| CK20-/CK7+ | Breast carcinoma, both ductal and lobular types Bronchoalveolar carcinoma of lung Endometrial carcinoma Malignant mesothelioma Non-small cell adenocarcinoma of lung Ovarian carcinoma other than mucinous tumor |
| CK20+/CK7- | Colorectal adenocarcinoma* |
| CK20-/CK7- | Hepatocellular carcinoma Prostatic adenocarcinoma Renal cell carcinoma Small cell neuroendocrine carcinoma of lung Squamous cell carcinoma of lung |
*Reduced or absent CK20 activity can be seen in colorectal carcinomas with high levels of microsatellite instability.
| Tumor subtype | CK7/CK20 profile | Fraction of cases positive (%) |
| Bladder transitional cell carcinoma |
CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
17/19 (89%) 2/19 (11%) 0/19 ( 0%) 0/19 (0%) |
| Colorectal adenocarcinoma | CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
4/40 (10%) 0/40 (0%) 30/40 (75%) 6/40 (15%) |
| Gastric adenocarcinoma | CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
11/29 (38%) 5/29 (17%) 10/29 (35%) 3/29 (10%) |
| Pancreatic adenocarcinoma | CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
15/23 (65%) 6/23 (26%) 2/23 (9%) 0/23 (0%) |
| Lung, non-small cell carcinoma |
CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
6/54 (11%) 39/54 (72%) 0/54 (0%) 9/54 (17%) |
| Lung, bronchiolo-alveolar carcinoma |
CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
0/3 (0%) 3/3 (100%) 0/3 (0%) 0/3 (0%) |
| Lung, squamous cell carcinoma |
CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
0/12 (0%) 0/12 (0%) 1/12 (8%) 11/12 (92%) |
| Lung, small cell carcinoma | CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
0/11 (0%) 2/11 (18%) 0/11 (0%) 9/11 (82%) |
| Hepatocellular carcinoma | CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
2/30 (7%) 5/30 (17%) 0/30 (0%) 23/30 (77%) |
| Ovary, serous and endometrioid carcinoma |
CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
0/19 (0%) 19/19 (100%) 0/19 (0%) 0/19 (0%) |
| Endometrial carcinoma | CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
3/25 (12%) 20/25 (80%) 0/25 (0%) 2/25 (8%) |
| Prostatic adenocarcinoma | CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
1/13 (8%) 1/13 (8%) 3/13 (23%) 8/13 (62%) |
| Renal cell carcinoma | CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
0/17 (0%) 4/17 (24%) 1/17 (6%) 12/17 (71%) |
| Breast, infiltrating ductal carcinoma |
CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
6/38 (16%) 31/38 (82%) 1/38 (3%) 0/38 (0%) |
| Breast, infiltrating lobular carcinoma |
CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
1/11 (9%) 10/11 (91%) 0/11 (0%) 0/11 (0%) |
| Malignant mesothelioma | CK7+/CK20+ CK7+/CK20- CK7-/CK20+ CK7-/CK20- |
0/16 (0%) 11/16 (69%) 0/16 (0%) 5/16 (31%) |
Specimen
Tissue
Submit a formalin-fixed, paraffin-embedded tissue
Formalin-fixed, paraffin-embedded (FFPE) tissue block
FFPE tissue section mounted on a charged, unstained slide
Ambient (preferred)
- Unlabeled/mislabeled block
- Insufficient tissue
- Slides broken beyond repair
Performance
AHL - Immunohistochemistry
Mo - Fr
1 - 2 days
Immunohistochemical staining and microscopic examination
Clinical and Interpretive info
If requested, an interpretive report will be provided
Specifications
- CK7 antibody recognizes human cytokeratin 7 intermediate filament protein, found in glandular and transitional epithelium
Staining pattern
- Cytoplasmic based
References
- Berezowski K, Stastny JF, Kornstein MJ: Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol 1996;9(4):426-429.
- Campbell F, Herrington CS: Application of cytokeratin 7 and 20 immunohistochemistry to diagnostic pathology. Curr Diagn Pathol 2001;7:113-122.
- Chu P, Wu E, Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000;13(9):962-972.
- Wang et.al., Appl Immunohistochem 3:99-107, 1995.
Billing
88342 - 1st stain
88341 - each additional stain
88341 - each additional stain
Tracking
12/19/2017
10/18/2018
01/12/2024